Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 13Terminated 3Recruiting 3Active not recruiting 2Unknown 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Dermatologic 39Head & Neck 8Genitourinary 6Thoracic 5Gynecologic 5Gastrointestinal 5Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2Lymphoid 2CNS 2Breast 2NET 1Endocrine 1

Conditions

Lymphoma 156Lymphoma, Non-Hodgkin 141Leukemia, Lymphocytic, Chronic, B-Cell 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Lymphoma, Follicular 112Lymphoma, Large B-Cell, Diffuse 111Lymphoma, Mantle-Cell 75Lymphoma, B-Cell 73Hodgkin Disease 63Multiple Myeloma 59Leukemia 55Burkitt Lymphoma 51Recurrence 49Lymphoma, B-Cell, Marginal Zone 48Leukemia, Myeloid, Acute 47Neoplasms 45Myelodysplastic Syndromes 42Hematologic Neoplasms 34Waldenstrom Macroglobulinemia 28Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Lymphoma, T-Cell 17Leukemia, Biphenotypic, Acute 16Leukemia, B-Cell 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Mycosis Fungoides 15Lymphoproliferative Disorders 15Lymphoma, T-Cell, Peripheral 15Myeloproliferative Disorders 14Lymphoma, T-Cell, Cutaneous 14Breast Neoplasms 14

Interventions

Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Skin Neoplasms × Lymphoid × Clear all
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmSarcomaThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT03212404 2025-02-03

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Checkpoint Therapeutics, Inc.

Phase 1 Active not recruiting
272 enrolled 1 FDA
DermatologicGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡